XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Development, Commercialization and Supply Agreement - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 31, 2023
Jun. 30, 2023
Feb. 28, 2023
Jan. 31, 2023
Jan. 31, 2022
Feb. 29, 2020
Jan. 31, 2020
Sep. 30, 2018
Sep. 30, 2017
Mar. 31, 2016
Feb. 28, 2015
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2018
Dec. 31, 2021
License And Collaboration Agreements [Line Items]                                    
Revenue recognized related to upfront and milestone payments                           $ 15,000,000 $ 1,012,000      
Licenses revenue                       $ 66,056,000 $ 89,878,000 232,198,000 278,948,000      
Deferred revenue                       4,974,000 15,697,000 4,974,000 15,697,000 $ 15,346,000   $ 16,709,000
Product Revenue, Net                                    
License And Collaboration Agreements [Line Items]                                    
Licenses revenue                       64,903,000 89,222,000 214,744,000 277,004,000      
Marine                                    
License And Collaboration Agreements [Line Items]                                    
Revenue recognized related to upfront and milestone payments                           3,900,000        
Mochida Pharmaceutical Co., Ltd. | In-licenses                                    
License And Collaboration Agreements [Line Items]                                    
Milestones payment       $ 1,000,000 $ 1,000,000                          
Mochida Pharmaceutical Co., Ltd. | In-licenses | Research and Development Expense                                    
License And Collaboration Agreements [Line Items]                                    
Up-front payment                                 $ 2,700,000  
Edding                                    
License And Collaboration Agreements [Line Items]                                    
Additional license revenues                       5,000,000   5,000,000        
Revenue recognized related to upfront and milestone payments                           5,000,000        
Edding | Out-licenses                                    
License And Collaboration Agreements [Line Items]                                    
Non-refundable up-front received                     $ 15,000,000              
Amounts to be received upon achievement of the regulatory milestone events                       33,000,000   33,000,000        
Milestone payments received                           6,000,000        
Sales-based milestone event payment                       120,000,000   120,000,000        
Revenue recognized related to upfront and milestone payments                           9,700,000 400,000      
Deferred revenue                       4,500,000   4,500,000   9,300,000    
Edding | Out-licenses | Licensing Revenue                                    
License And Collaboration Agreements [Line Items]                                    
Licenses revenue                           17,500,000   7,700,000    
Edding | Out-licenses | Product Revenue, Net                                    
License And Collaboration Agreements [Line Items]                                    
Licenses revenue                       300,000   300,000        
Edding | Out-licenses | Maximum                                    
License And Collaboration Agreements [Line Items]                                    
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                       148,000,000   148,000,000        
Amounts to be received upon achievement of the regulatory milestone events                       15,000,000   15,000,000        
Sales-based milestone event payment                       50,000,000   50,000,000        
Edding | Out-licenses | Minimum                                    
License And Collaboration Agreements [Line Items]                                    
Amounts to be received upon achievement of the regulatory milestone events                       2,000,000   2,000,000        
Sales-based milestone event payment                       5,000,000   5,000,000        
Edding | Out-licenses | Clinical Trial Application                                    
License And Collaboration Agreements [Line Items]                                    
Non-refundable milestone payment received                   $ 1,000,000                
Edding | Out-licenses | Marine                                    
License And Collaboration Agreements [Line Items]                                    
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                       3,900,000   3,900,000        
Additional license revenues                       5,000,000   5,000,000        
Remaining performance period amount                       1,100,000   1,100,000        
Reduction in net loss                           5,000,000        
Edding | Out-licenses | Marine | VASCEPA                                    
License And Collaboration Agreements [Line Items]                                    
Non-refundable milestone payment received   $ 5,000,000                       $ 5,000,000        
Edding | Out-licenses | Marine | Maximum                                    
License And Collaboration Agreements [Line Items]                                    
Revenue recognition period of non-refundable up-front payment                           3 years        
Edding | Out-licenses | Marine | Minimum                                    
License And Collaboration Agreements [Line Items]                                    
Revenue recognition period of non-refundable up-front payment                           11 years        
Biologix FZCo                                    
License And Collaboration Agreements [Line Items]                                    
Revenue recognition period of non-refundable up-front payment                           8 years        
Biologix FZCo | Out-licenses                                    
License And Collaboration Agreements [Line Items]                                    
Non-refundable milestone payment received                           $ 5,300,000        
Revenue recognition period of non-refundable up-front payment                   10 years                
Reduction in net loss                           5,300,000        
Biologix FZCo | Out-licenses | Product Revenue, Net                                    
License And Collaboration Agreements [Line Items]                                    
Licenses revenue                       1,400,000   2,000,000        
HLS                                    
License And Collaboration Agreements [Line Items]                                    
Additional license revenues                       5,300,000   5,300,000        
Revenue recognized related to upfront and milestone payments                           5,300,000        
HLS | Out-licenses                                    
License And Collaboration Agreements [Line Items]                                    
Non-refundable up-front received                 $ 5,000,000                  
Non-refundable milestone payment received           $ 2,500,000 $ 3,800,000 $ 2,500,000                    
Revenue recognized related to upfront and milestone payments                           5,600,000 500,000      
Deferred revenue                               5,600,000    
Non-refundable up-front received period                 6 months                  
Non-refundable milestone payment received                 $ 3,800,000                  
HLS | Out-licenses | Health Canada                                    
License And Collaboration Agreements [Line Items]                                    
Non-refundable milestone payment received                 2,500,000                  
HLS | Out-licenses | Licensing Revenue                                    
License And Collaboration Agreements [Line Items]                                    
Licenses revenue                           13,800,000   $ 8,200,000    
HLS | Out-licenses | Product Revenue, Net                                    
License And Collaboration Agreements [Line Items]                                    
Licenses revenue                       0 $ 600,000 1,600,000 $ 2,900,000      
HLS | Out-licenses | Maximum                                    
License And Collaboration Agreements [Line Items]                                    
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                 50,000,000                  
HLS | Out-licenses | Achievement of REDUCE-IT Trial                                    
License And Collaboration Agreements [Line Items]                                    
Non-refundable milestone payment received                 $ 2,500,000                  
CSL Seqirus | Out-licenses                                    
License And Collaboration Agreements [Line Items]                                    
Non-refundable up-front received     $ 500,000                              
Licenses revenue                           500,000        
Upfront payment receivable     500,000                              
Event-related milestone payments receivable     8,000,000                              
Additional product-related milestone payments receivable     $ 4,000,000                              
Lotus Pharmaceuticals | VAZKEPA                                    
License And Collaboration Agreements [Line Items]                                    
Non-refundable up-front received $ 300,000                                  
Upfront payment receivable $ 300,000                                  
Lotus Pharmaceuticals | Out-licenses                                    
License And Collaboration Agreements [Line Items]                                    
Licenses revenue                       $ 300,000   $ 300,000